122 related articles for article (PubMed ID: 21664971)
1. Iodine-131-lipiodol therapy in hepatic tumours.
Ahmadzadehfar H; Sabet A; Wilhelm K; Biersack HJ; Risse J
Methods; 2011 Nov; 55(3):246-52. PubMed ID: 21664971
[TBL] [Abstract][Full Text] [Related]
2. Therapy of hepatocellular cancer with iodine-131-Lipiodol.
Risse JH; Menzel C; Grünwald F; Strunk H; Biersack HJ; Palmedo H
Rom J Gastroenterol; 2004 Jun; 13(2):119-24. PubMed ID: 15229776
[TBL] [Abstract][Full Text] [Related]
3. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
[TBL] [Abstract][Full Text] [Related]
4. Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads.
Guiu B; Deschamps F; Aho S; Munck F; Dromain C; Boige V; Malka D; Leboulleux S; Ducreux M; Schlumberger M; Baudin E; de Baere T
J Hepatol; 2012 Mar; 56(3):609-17. PubMed ID: 22027582
[TBL] [Abstract][Full Text] [Related]
5. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma.
Okabe K; Beppu T; Haraoka K; Oh-Uchida Y; Yamamura S; Tomiyasu S; Yamanaka T; Sano O; Masuda T; Chikamoto A; Fujiyama S; Baba H
Anticancer Res; 2011 Sep; 31(9):2983-8. PubMed ID: 21868548
[TBL] [Abstract][Full Text] [Related]
6. Treatment of unresectable hepatocellular carcinoma with radiolabelled lipiodol.
Kanhere HA; Leopardi LN; Fischer L; Kitchener MI; Maddern GJ
ANZ J Surg; 2008 May; 78(5):371-6. PubMed ID: 18380736
[TBL] [Abstract][Full Text] [Related]
7. Comparative survival analysis of adjuvant therapy with iodine-131-labeled lipiodol to hepatic resection of primary hepatocellular carcinoma: a meta-analysis.
Gong L; Shi L; Sun J; Yuan WS; Chen JF; Liu P; Gong F; Dong JH
Nucl Med Commun; 2014 May; 35(5):484-92. PubMed ID: 24492679
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival.
Lau WY; Lai EC; Leung TW; Yu SC
Ann Surg; 2008 Jan; 247(1):43-8. PubMed ID: 18156922
[TBL] [Abstract][Full Text] [Related]
9. 131-iodine Lipiodol therapy in hepatocellular carcinoma.
Raoul JL; Boucher E; Roland V; Garin E
Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):348-55. PubMed ID: 19521315
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma.
Boucher E; Corbinais S; Rolland Y; Bourguet P; Guyader D; Boudjema K; Meunier B; Raoul JL
Hepatology; 2003 Nov; 38(5):1237-41. PubMed ID: 14578862
[TBL] [Abstract][Full Text] [Related]
11. Internal radiation by 131-iodine lipiodol in unresectable hepatocellular carcinoma.
Tabone M; Carbonatto P; Calvo A; Pellerito R; Stasi M; Daperno M; Rocca R
Dig Liver Dis; 2013 Nov; 45(11):962-3. PubMed ID: 23587497
[No Abstract] [Full Text] [Related]
12. Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis.
Chua TC; Saxena A; Chu F; Butler SP; Quinn RJ; Glenn D; Morris DL
Int J Clin Oncol; 2011 Apr; 16(2):125-32. PubMed ID: 21061140
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant I-131 Lipiodol After Resection or Radiofrequency Ablation for Hepatocellular Carcinoma.
Schwarz L; Bubenheim M; Gardin I; Huet E; Riachi G; Clavier E; Goria O; Vera P; Scotté M
World J Surg; 2016 Aug; 40(8):1941-50. PubMed ID: 27098539
[TBL] [Abstract][Full Text] [Related]
14. Increased Lipiodol uptake in hepatocellular carcinoma possibly due to increased membrane fluidity by dexamethasone and tamoxifen.
Becker S; Ardisson V; Lepareur N; Sergent O; Bayat S; Noiret N; Gaboriau F; Clément B; Boucher E; Raoul JL; Garin E
Nucl Med Biol; 2010 Oct; 37(7):777-84. PubMed ID: 20870152
[TBL] [Abstract][Full Text] [Related]
15. Treatment of unresectable hepatocellular carcinoma: targeted therapies using iodized oil.
Bhattacharya S; Dusheiko GM
Princess Takamatsu Symp; 1995; 25():253-64. PubMed ID: 8875631
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support.
Raoul JL; Guyader D; Bretagne JF; Duvauferrier R; Bourguet P; Bekhechi D; Deugnier YM; Gosselin M
J Nucl Med; 1994 Nov; 35(11):1782-7. PubMed ID: 7525901
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for the leakage of chemotherapeutic agents into systemic circulation after transcatheter arterial chemoembolization of hepatocellular carcinoma.
Hsieh MY; Lin ZY; Chen SH; Chuang WL
Kaohsiung J Med Sci; 2011 Oct; 27(10):431-6. PubMed ID: 21943814
[TBL] [Abstract][Full Text] [Related]
18. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma.
Raoul JL; Guyader D; Bretagne JF; Heautot JF; Duvauferrier R; Bourguet P; Bekhechi D; Deugnier YM; Gosselin M
Hepatology; 1997 Nov; 26(5):1156-61. PubMed ID: 9362356
[TBL] [Abstract][Full Text] [Related]
19. Transcatheter arterial chemoembolization with fine-powder cisplatin-lipiodol for HCC.
Koizumi Y; Hirooka M; Uehara T; Kisaka Y; Uesugi K; Kumagi T; Abe M; Matsuura B; Hiasa Y; Onji M
Hepatogastroenterology; 2011; 58(106):512-5. PubMed ID: 21661422
[TBL] [Abstract][Full Text] [Related]
20. Intra-arterial iodine-131-lipiodol for unresectable hepatocellular carcinoma.
Chua TC; Chu F; Butler SP; Quinn RJ; Glenn D; Liauw W; Morris DL
Cancer; 2010 Sep; 116(17):4069-77. PubMed ID: 20564150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
